Advanced liver cancer market seen reaching $4.27 billion by 2030

The advanced liver cancer market is projected to grow from $2.49 billion in 2026 to $4.27 billion by 2030, driven by rising hepatitis infections, broader use of genomic testing, and expanding diagnostic capacity. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Advanced liver cancer is a late-stage disease with limited treatment options, so faster diagnosis and more personalized care can change outcomes. - The market’s growth reflects rising demand for imaging, biopsy, genomic testing, and specialized cancer care. - The expansion also signals bigger spending on diagnostics, treatment centers, and research tied to liver cancer.

What happened: - The Business Research Company released its Advanced Liver Cancer Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 30, 2026. - The report estimates the advanced liver cancer market will grow from $2.16 billion in 2025 to $2.49 billion in 2026. - The report projects the market will reach $4.27 billion by 2030. - The forecast implies a 14.8% CAGR for 2025-2026 and a 14.5% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - The report ties recent growth to higher liver cancer incidence, broader CT and MRI adoption, stronger biopsy demand, more cancer research funding, and the expansion of diagnostic centers and academic institutions. - Future growth is linked to genomic testing, personalized medicine, better screening, predictive diagnostics, more hospital-research partnerships, and more ambulatory surgical centers. - The report identifies next-generation sequencing and genomic tests for hepatocellular carcinoma as major trends. - The report also points to wider use of imaging and biopsy techniques, more prognostic and predictive diagnostics, expanded liver cancer research, and stronger focus on early detection and customized treatment. - Advanced liver cancer, often called late-stage hepatocellular carcinoma, refers to cancer that has spread beyond the liver or grown enough to significantly affect liver function. - The disease can invade nearby blood vessels, lymph nodes, or distant organs. - Common symptoms include jaundice, abdominal discomfort, unintended weight loss, and persistent fatigue. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising long-term hepatitis B and hepatitis C infections remain a major market driver because persistent infection can lead to cirrhosis and liver cancer. - The report cites inadequate screening, weak vaccination coverage, and delayed treatment access as contributors to those infections. - In April 2025, Australia-based health professional organization ASHM reported that about 219,800 people in Australia were living with chronic hepatitis B in 2023, equal to about 0.82% of the population. - The market outlook suggests diagnostics are becoming more important not just for detection, but for tailoring treatment earlier in the disease course. - The regional split points to mature demand in North America and faster unmet-need growth in Asia-Pacific, where liver disease burden remains high.

What's next: - The report expects more adoption of genomic testing and personalized medicine as healthcare systems look for better risk stratification and treatment matching. - Hospitals, researchers, and diagnostic providers are likely to deepen collaborations as advanced liver cancer care shifts toward earlier detection and precision workflows. - Expansion of ambulatory surgical centers may add more capacity for diagnosis and treatment delivery. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated graphics and tables.

The bottom line: - Advanced liver cancer is becoming a bigger global market as diagnostics, genomics, and care coordination improve, but the disease burden from chronic hepatitis keeps demand high.